{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:57:43Z","timestamp":1777748263122,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10792-021-01919-6","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T06:02:47Z","timestamp":1624514567000},"page":"3523-3531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-tumor necrosis factor-alpha therapy for refractory uveitic optic disk neovascularization in\u00a0active\u00a0non-infectious posterior and panuveitis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-4254","authenticated-orcid":false,"given":"Radgonde","family":"Amer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"issue":"3","key":"1919_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ophtha.2015.10.056","volume":"123","author":"AK Patel","year":"2016","unstructured":"Patel AK, Newcomb CW, Liesegang TL et al (2016) Systemic immunosuppressive therapy for eye diseases research group risk of retinal neovascularization in cases of uveitis. Ophthalmology 123(3):646\u2013654","journal-title":"Ophthalmology"},{"key":"1919_CR2","volume-title":"Chapter 26 - basic mechanisms of pathological retinal and choroidal angiogenesis","author":"DG Vavvas","year":"2013","unstructured":"Vavvas DG, Miller JW (2013) Chapter 26 - basic mechanisms of pathological retinal and choroidal angiogenesis. Elsevier Inc"},{"issue":"2","key":"1919_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0002-9394(76)90415-3","volume":"82","author":"SR Shorb","year":"1976","unstructured":"Shorb SR, Irvine AR, Kimura SJ (1976) Optic disk neovascularization associated with chronic uveitis. Am J Ophthalmol 82(2):175\u2013178","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1919_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10384-005-0307-8","volume":"50","author":"I Tugal-tutkun","year":"2006","unstructured":"Tugal-tutkun I, Onal S, Altan-Yaycioglu R, Urgancioglu M (2006) Neovascularization of the optic disc in beh\u00e7et\u2019s disease. Jpn J Ophthalmol 50(3):256\u2013265","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"1919_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaapos.2017.05.028","volume":"21","author":"E Interlandi","year":"2017","unstructured":"Interlandi E, Latanza L, Pellegrini F, Pavesio C (2017) Regression of unusual optic disk neovascularization after adalimumab in a case of juvenile idiopathic arthritis-related uveitis. J AAPOS 21(5):412\u2013414","journal-title":"J AAPOS"},{"issue":"6","key":"1919_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/jop.2010.0031","volume":"26","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M (2010) Regression of optic disc neovascularization in patients with Beh\u00e7et\u2019s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 26(6):627\u2013630","journal-title":"J Ocul Pharmacol Ther"},{"key":"1919_CR7","doi-asserted-by":"crossref","unstructured":"Ambrosio ED, Tortorella P, Lannetti L (2014) Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy. J Ophthalmol 2014:450428","DOI":"10.1155\/2014\/450428"},{"issue":"6","key":"1919_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S0002-9394(00)00598-5","volume":"130","author":"SR Sanislo","year":"2000","unstructured":"Sanislo SR, Lowder CY, Kaiser PK, Gutman FA, Zegarra H, Dodds EM, Dailey JP, Meisler DM, Cunningham ET (2000) Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis. Am J Ophthalmol 130(6):724\u2013731","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1919_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","volume":"144","author":"J Plskova","year":"2007","unstructured":"Plskova J, Greiner K, Forrester JV (2007) Interferon-\u03b1 as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55\u201361","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1919_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/112067210401400515","volume":"14","author":"F Giansanti","year":"2004","unstructured":"Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U (2004) Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease. Eur J Ophthalmol 14(5):445\u2013448","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1919_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273948.2017.1332228","volume":"27","author":"NN Markomichelakis","year":"2019","unstructured":"Markomichelakis NN, Aissopou EK, Maselos S, Tugal-Tutkun I, Sfikakis PP (2019) Biologic treatment options for retinal neovascularization in beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 27(1):51\u201357","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1919_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/a-0800-8066","volume":"236","author":"I Papasavvas","year":"2019","unstructured":"Papasavvas I, Ambresin A, Pournaras JA, Henchoz L, Vaudaux J (2019) Regression of optic disc neovascularization (NVD) in a patient with behcet\u2019s disease treated with oral corticosteroids and adalimumab (ADA). Klin Monbl Augenheilkd 236(4):578\u2013580","journal-title":"Klin Monbl Augenheilkd"},{"key":"1919_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"1919_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467\u2013471","journal-title":"Ophthalmology"},{"issue":"4","key":"1919_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00006982-199010000-00008","volume":"10","author":"PH Kalina","year":"1990","unstructured":"Kalina PH, Pach JM, Buettner H, Robertson DM (1990) Neovascularization of the disc in pars planitis. Retina 10(4):269\u2013273","journal-title":"Retina"},{"issue":"1","key":"1919_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias GD, Ivashkiv LB (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 12(1):49\u201362","journal-title":"Nat Rev Rheumatol"},{"key":"1919_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M Santos Lacomba","year":"2001","unstructured":"Santos Lacomba M, Marcos Mart\u00edn C, Gallardo Galaera JM, G\u00f3mez Vidal MA, Collantes Est\u00e9vez E, Ram\u00edrez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251\u2013255","journal-title":"Ophthalmic Res"},{"issue":"2","key":"1919_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1185\/030079903125002847","volume":"20","author":"V P\u00e9rez-Guijo","year":"2004","unstructured":"P\u00e9rez-Guijo V, Santos-Lacomba M, S\u00e1nchez-Hern\u00e1ndez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Est\u00e9vez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20(2):155\u2013157","journal-title":"Curr Med Res Opin"},{"key":"1919_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-082708-100732","volume":"27","author":"M Feldmann","year":"2009","unstructured":"Feldmann M (2009) Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 27:1\u201327","journal-title":"Annu Rev Immunol"},{"key":"1919_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/ard.62.2.100","volume":"62","author":"EM Gravallese","year":"2003","unstructured":"Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A et al (2003) Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. AnnU Rheum Dis 62:100\u2013107","journal-title":"AnnU Rheum Dis"},{"key":"1919_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2011.04.020","volume":"10","author":"A Marrelli","year":"2011","unstructured":"Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R et al (2011) Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 10:595\u2013598","journal-title":"Autoimmun Rev"},{"key":"1919_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/art.37853","volume":"65","author":"A Lee","year":"2013","unstructured":"Lee A et al (2013) Tumor necrosis factor \u03b1 induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthr Rheum 65:928\u2013938","journal-title":"Arthr Rheum"},{"key":"1919_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.11143","volume":"48","author":"H Nakahara","year":"2003","unstructured":"Nakahara H, Song J, Sugimoto M et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthr Rheum 48:1521\u20131529","journal-title":"Arthr Rheum"},{"key":"1919_CR24","first-page":"710","volume":"131","author":"N Maruo","year":"1992","unstructured":"Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases endothelial permeability in vitro. Endocrinology 131:710\u2013714","journal-title":"Endocrinology"},{"key":"1919_CR25","first-page":"99","volume":"1","author":"SA Vinores","year":"1997","unstructured":"Vinores SA, Youssri AI, Luna JD et al (1997) Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1:99\u2013109","journal-title":"Histol Histopathol"},{"issue":"11","key":"1919_CR26","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Adan","year":"2013","unstructured":"Adan A, Mesquida M, Llorenc\u00b8 V, et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251(11):2627\u20132632","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"1919_CR27","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","volume":"121","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Molins B, Llorenc\u00b8 V, Sainz de la Maza M, Adan A, (2014) Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 121(12):2380\u20132386","journal-title":"Ophthalmology"},{"issue":"7","key":"1919_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","volume":"38","author":"M Mesquida","year":"2018","unstructured":"Mesquida M, MolinsLlorenc BV et al (2018) Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina 38(7):1361\u20131370","journal-title":"Retina"},{"key":"1919_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah YJ, Sadiq MA, Chu DS et al (2017) Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis. Am J Ophthalmol 183:71\u201380","journal-title":"Am J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01919-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-01919-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01919-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T09:05:30Z","timestamp":1632042330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-01919-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-01919-6","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oren Cohen: Not applicable. Radgonde Amer: lecturer, AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}